셀트리온, 종합제약사 도약•••다케다 아•태 사업 인수<br /><br />South Korean biopharmaceutical company Celltrion will acquire the business rights for a total of 18 brands belonging to Japan's Takeda Pharmaceutical ... the first major deal for the Korean firm in upgrading its global presence.<br />Under the 278 million U.S. dollar deal, Celltrion will secure the patents, trademarks and sales rights of the products in nine Asia-Pacific markets, including South Korea, Australia and Singapore.<br />The 18 brands raked in combined sales of 140 million dollars in the region in 2018 alone.<br />Celltrion said it will be on the market through its affiliates Celltrion Pharma and Celltrion Healthcare.<br />The company had a market value of 247 million dollars last year,.. up over 17-and-a-half percent on-year.<br />
